Castle Biosciences Inc (CSTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has a cash flow conversion efficiency ratio of 0.032x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.20 Million) by net assets ($470.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Castle Biosciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Castle Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Castle Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Castle Biosciences Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Castle Biosciences Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AFCONS INFRASTRUCTURE LTD
NSE:AFCONS
|
-0.124x |
|
Bk Harda Internasional Tbk Pt
JK:BBHI
|
0.052x |
|
ZEAL Network SE
XETRA:TIMA
|
0.163x |
|
Ye Chiu Metal Recycling China Ltd
SHG:601388
|
-0.026x |
|
Hanza AB
ST:HANZA
|
0.066x |
|
Nobia AB
ST:NOBI
|
-0.026x |
|
Suzhou Delphi Laser Co. Ltd. A
SHG:688170
|
N/A |
|
Wuhan Fingu Electronic Technology Co Ltd
SHE:002194
|
0.036x |
Annual Cash Flow Conversion Efficiency for Castle Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Castle Biosciences Inc from 2017 to 2025. View Castle Biosciences Inc (CSTL) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $470.87 Million | $64.35 Million | 0.137x | -3.97% |
| 2024-12-31 | $455.83 Million | $64.87 Million | 0.142x | +1089.66% |
| 2023-12-31 | $391.27 Million | $-5.63 Million | -0.014x | +86.22% |
| 2022-12-31 | $399.15 Million | $-41.66 Million | -0.104x | -126.35% |
| 2021-12-31 | $411.74 Million | $-18.98 Million | -0.046x | -294.27% |
| 2020-12-31 | $415.69 Million | $9.87 Million | 0.024x | -71.21% |
| 2019-12-31 | $85.11 Million | $7.01 Million | 0.082x | -93.25% |
| 2018-12-31 | $-10.07 Million | $-12.29 Million | 1.221x | +42.44% |
| 2017-12-31 | $-14.27 Million | $-12.23 Million | 0.857x | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more